Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Official Title

An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)

Details

Keywords

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma, Non-Hodgkin Lymphoma, NHL, Relapsed, Refractory, Novel class, Pivotal, Phase 3, Hematologic disease, Neoplasm, Plasma cell neoplasms, Paraproteinemias, Lymphoma, Immunoproliferative disorder, Blood protein disorders, Lymphoproliferative disorders, Antineoplastic agents, Leukemia, Lymphocytic, Chronic, B-Cell, Mantle-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose, Iopofosine I 131, intravenous administration WM, Iopofosine I 131, intravenous administration MM, Iopofosine I 131, intravenous administration CNS Lymphoma, Iopofosine I 131 intravenous administration NHL [CLOSED]

Eligibility

Locations

  • Cellectar Biosciences site
    Los Angeles California 90095 United States
  • Cellectar Biosciences site
    Redlands California 92373 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cellectar Biosciences, Inc.
ID
NCT02952508
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 120 study participants
Last Updated